5-Amino-3,4-dimethylisoxazole → N-(3,4-dimethylisoxazol-5-yl)-4-(3-{[5-(trifluoromethyl)pyridin-2-yl]oxy}benzylidene)piperidine-1-carboxamide

참여 물질

반응 단계

Following the procedure in Example 1, Step 6, 2-(3-piperidin-4-ylidenemethyl-phenoxy)-5-trifluoromethyl-pyridine hydrochloride (150 mg, 0.40 mmol, from Example 1, Step 5) and phenyl 3,4-dimethylisoxazol-5-ylcarbamate (94 mg, 0.40 mmol, prepared according to the procedure described in Synthesis, 1997, 1189-1194 from 5-amino-3,4-dimethylisoxazole) were used to provide the title compound (187 mg). MS (APCI 10V) AP+ 473.3, AP− 471.2; 1H NMR (400 MHz, CD3OD) δ ppm 1.83 (s, 3H) 2.18 (s, 3H) 2.41-2.49 (m, 2H) 2.53-2.62 (m, 2H) 3.49-3.57 (m, 2H) 3.58-3.66 (m, 2H) 6.46 (s, 1H) 6.97-7.05 (m, 2H) 7.10-7.20 (m, 2H) 7.40 (tt, J=7.64, 0.76 Hz, 1H) 8.08 (dd, J=8.65, 2.51 Hz, 1H) 8.33-8.51 (m, J=2.31, 1.33, 0.88, 0.74 Hz, 1H).

출처 및 근거